Browse drugs

…eConclusions In these preliminary findings of obe-cel in srSLE, obe-cel demonstrated a favourable safety profile and clinical benefit d…

…ity.Methods Pts with SLE/LN received a single administration of CTA313 treatment at 3 dose levels (DLs): DL1 3×106 CAR+ T cells/kg, DL…

…matched healthy controls. A subgroup of 5 patients treated with Anifrolumab and 5 with Belimumab were evaluated longitudinally, with sample…

…flammatory skin condition with no approved targeted treatments. Afimetoran – a first-in-class, once daily oral, selective, equipotent, sma…

…1 (56.6%), preserved FEV1/FVC ratio. Treatment with enoxaparin, furosemide, sildenafil, ivabradine and bosentan was initiated.After 3 mont…

…d APS, refractory to glucocorticoids, successfully treated with ravulizumab, a terminal complement inhibitor.Methods A 30-year-old woman wi…

…cline in use of cyclophosphamide from 2013 onwards. Ever-use of mycophenolate began to rise from the group recruited from1994 onwards and bio…

…h high baseline serum IgA2 anti-dsDNA antibodies, compared with rituximab alone. This biomarker-enrichment trial was developed from the i…

…ntenance in 69% of cases, a total of 14.5% of patients received rituximab as a rescue therapy, while 20.3% were treated with CYC as a rei…

…ntric Castleman disease was done, and interleukin 6 antagonist, siltuximab, was given every 4 weeks. Subsequently, the patient developed h…

…A 1:1280, anti-dsDNA positive, low C3/C4). Initial therapy with hydroxychloroquine (200 mg/day) and low-dose prednisone (7.5 mg/day) achieved clin…

…on (IFN) pathway activation and myeloid- and B-cell activation. Enpatoran is a novel, first-in-class, oral TLR7/8 inhibitor. In a Phase 2…